Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom, a hyaluronic acid product for the treatment of knee osteoarthritis.

With the reacquisition of Synocrom, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom serving as a key pillar of its offering.

Synocrom is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history.

The reintroduction of Synocrom also builds on Croma-Pharma’s long-standing expertise in the development and manufacturing of hyaluronic acid prefilled syringes and reflects the company’s commitment to providing reliable, high-quality solutions for everyday clinical practice.

In clinical practice, hyaluronic acid injections are widely used in the treatment of knee osteoarthritis. As a naturally occurring component of synovial fluid, hyaluronic acid contributes to joint lubrication and function, and may help alleviate symptoms associated with degenerative joint changes.

Synocrom is an MDR-certified product that meets stringent EU regulatory requirements, ensuring safe, controlled, and standardised use in the treatment of knee osteoarthritis. It is based on biologically derived hyaluronic acid and has been clinically established through three decades of use in routine practice. The product also demonstrates a favourable tolerability profile, established through routine clinical use.

Synocrom will be available to healthcare professionals in the EU and Switzerland from May 2026. Its return underlines Croma-Pharma’s ambition to build a focused and innovation-driven orthopaedics portfolio while building on the company’s proven expertise and long-standing market heritage.